Displaying drugs 726 - 750 of 831 in total
Lubazodone
Lubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was discontinued. It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.
Experimental
Matched Description: … being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II …
Calcium
Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the...
Nutraceutical
Matched Mixtures name: … Vc II ... Multipack II ... Card-floe II Tab …
ALT-2074
An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.
Investigational
Matched Description: … An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative …
Alunacedase alfa
Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
Investigational
Sagopilone
Sagopilone has been used in trials studying the treatment of Melanoma, Neoplasms, CNS Disease, Breast Cancer, and Breast Neoplasms, among others. It is a so-called fully synthetic epothilone and is the first such compound to be in clinical development to combat several forms of cancer. Epothilones are 16-member ring macrolides...
Investigational
Matched Description: … Sagopilone has been used in trials studying the treatment of Melanoma, Neoplasms, CNS Disease, Breast …
AZD0947
AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.
Investigational
Matched Description: … As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared …
LErafAON
NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.
Investigational
Matched Description: … Phase I/II trials commenced in March 2001 and were ongoing as of June 2003. …
EVT 201
EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Investigational
Nadifloxacin
Nadifloxacin has been used in trials studying the treatment of Acne Vulgaris.
Investigational
Matched Categories: … Topoisomerase II Inhibitors …
AVR-RD-05
AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced ex vivo with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).
Investigational
Matched Description: … It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII) …
IR208
IR208 is a synthetic T-Cell receptor peptide
vaccine developed by Immune Response Corporation.
It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients. IR208 is currently undergoing Phase II
studies in a 200-patient trial.
Investigational
Matched Description: … IR208 is currently undergoing Phase II
studies in a 200-patient trial. …
Brasofensine
Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Investigational
Matched Description: … Phase I/II trials for brasofensine have been completed in the U.K. …
QazCovid-in
The QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems . It demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].
Investigational
Matched Description: … It demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357 …
Lucanthone
One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
Investigational
AGRO100
AGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells. Such binding leads to internalization of the complex, and a strong anti-proliferative response in the tumor cell.
Pre-clinical testing demonstrates that...
Investigational
Matched Description: … of the disease, including lung, prostate, breast, cervical, and colon cancer, as well as malignant melanoma …
Balsam of Peru
Balsam of Peru is a resin that comes from the tree Myroxylon balsamum pereirae. It is constituted by a mixture of substances from which the major components are benzyl cinnamate and DB00676. Balsam of Peru has also presented several allergens such as cinnamic acid, DB06770 and DB02130. Under the FDA,...
Nutraceutical
Vet approved
Matched Mixtures name: … Stroke II Synergy …
EpiVacCorona
EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus . It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613].
Investigational
Matched Description: … It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575 …
Bezitramide
Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's , and marketed under the name Burgodin. After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market.
Bezitramide has never been FDA approved and is currently a schedule...
Experimental
Illicit
Withdrawn
Matched Description: … Bezitramide has never been FDA approved and is currently a schedule II drug. …
Flupirtine
Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
Investigational
Matched Description: … It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment …
4'-Methylene-5,8,10-trideazaaminopterin
CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier (RFC) system than is Methotrexate. It has been investigated for the treatment of Rheumatoid Arthritis (phase II).
Investigational
Matched Description: … It has been investigated for the treatment of Rheumatoid Arthritis (phase II). …
Iron polymaltose
Experimental
CCX915
CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and...
Investigational
Matched Description: … thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II …
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
Displaying drugs 726 - 750 of 831 in total